Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
J.H. Whitney Equity Partners VII, LLC, a significant stakeholder in Aveanna Healthcare Holdings , Inc. (NASDAQ:AVAH), recently sold shares worth approximately $102,488 over two consecutive days. The transactions were executed as part of a pre-established trading plan. The sales come amid a remarkable period for AVAH, which has delivered a 112.8% return over the past year, according to InvestingPro data.
On April 1, the firm sold 3,610 shares at a weighted average price of $5.63 per share, followed by an additional sale of 8,166 shares on April 2 at the same average price. These sales were part of a larger plan involving multiple transactions at prices ranging from $5.62 to $5.67 on the first day and $5.62 to $5.65 on the second day. With analyst targets ranging from $4.50 to $7.00, InvestingPro subscribers can access 7 additional key insights and a comprehensive Pro Research Report for deeper analysis.
The sales were made indirectly through J.H. Whitney VII, L.P., PSA Healthcare Investment Holding LLC, and PSA Iliad Holdings LLC, entities associated with J.H. Whitney Equity Partners. Following these transactions, the entities still hold a substantial number of shares in Aveanna Healthcare Holdings, which currently maintains a market capitalization of $1.04 billion.
In other recent news, Aveanna Healthcare Holdings Inc. reported stronger-than-expected financial results for the fourth quarter of 2024, with earnings per share of $0.05, surpassing the forecasted loss of $0.003. Revenue also exceeded expectations, coming in at $519.9 million against a forecast of $499.07 million. Aveanna Healthcare announced an agreement to acquire Thrive Skilled Pediatric Care, which will expand its services into two new states and strengthen its presence in existing markets. This acquisition is expected to enhance Aveanna’s service offerings and market reach, pending regulatory approvals.
Additionally, Aveanna Healthcare announced the resignation of Dr. Sheldon Retchin from its Board of Directors due to personal health concerns. Moody’s Ratings affirmed Aveanna Healthcare’s Caa1 rating, reflecting an improvement in business performance and a decrease in leverage, with the outlook revised to positive from stable. UBS updated its price target for Aveanna Healthcare, raising it to $4.50, while maintaining a Sell rating. These developments highlight Aveanna’s strategic moves and financial performance as the company navigates its growth and operational strategies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.